Literature DB >> 26364550

Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?

Anthony V D'Amico1.   

Abstract

Synthesis of data from randomized trials suggests that long-term versus short-term androgen deprivation therapy may be most effective in men with Gleason grade 4 prostate cancer (PCa) and less or ineffective in men with Gleason grade 5 PCa.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26364550     DOI： 10.1016/j.eururo.2015.08.057

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  5 in total

1.  Is Androgen Deprivation Therapy "Another Deficient Therapy" for Gleason Score 9-10 Prostate Cancer?

Authors:  Matthew P Deek; Ryan M Phillips; Michael Haffner; Phuoc T Tran
Journal:  Eur Urol       Date:  2018-09-26       Impact factor: 20.096

2.  Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Authors:  Amar U Kishan; Xiaoyan Wang; Wendy Seiferheld; Laurence Collette; Kiri A Sandler; Howard M Sandler; Michel Bolla; Philippe Maingon; Theo De Reijke; Gerald E Hanks; Nicholas G Nickols; Matthew Rettig; Alexandra Drakaki; Robert E Reiter; Daniel E Spratt; Patrick A Kupelian; Michael L Steinberg; Christopher R King
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

3.  Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.

Authors:  Bumjin Lim; Wonchul Lee; Yoon Soo Kyung; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-04       Impact factor: 4.553

4.  Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis.

Authors:  Zhigang Yuan; Daniel Fernandez; Jasreman Dhillon; Julieta Abraham-Miranda; Shivanshu Awasthi; Youngchul Kim; Jingsong Zhang; Rohit Jain; Amparo Serna; Julio M Pow-Sang; Michael Poch; Roger Li; Brandon Manley; Angelina Fink; Arash Naghavi; Javier F Torres-Roca; G Daniel Grass; Sungjune Kim; Kujtim Latifi; Dylan Hunt; Peter A S Johnstone; Kosj Yamoah
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-07-10       Impact factor: 5.554

5.  Androgen deprivation therapy in high risk prostate cancer.

Authors:  Ritchell Van Dams; Amar U Kishan
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.